版本:
中国

BRIEF-Moleculin Biotech says working to resubmit IND application for annamycin

May 23 Moleculin Biotech Inc

* Moleculin Biotech issues shareholder update on FDA designation of orphan drug and IND status for annamycin

* Moleculin Biotech - working to resubmit IND application for annamycin and to announce co may begin Phase I/II clinical trials by end of July of 2017

* Moleculin Biotech - if unable to obtain CMC data on timely basis,will delay resubmitting ind application for annamycin,which will delay clinical trials Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐